Literature DB >> 24157221

Impaired systolic blood dipping and nocturnal hypertension: an independent predictor of carotid intima-media thickness in type 1 diabetic patients.

Mehmet Emre Atabek1, Nesibe Akyürek2, Beray Selver Eklioglu1, Hayrullah Alp3.   

Abstract

OBJECTIVE: Type 1 diabetes in children predicts a broad range of later health problems including an increased risk of cardiovascular morbidity and mortality. This study aimed to evaluate whether nocturnal hypertension and impaired nocturnal dipping affect atherosclerosis in children and adolescents with type 1 diabetes and to investigate the relationship between atherogenic risk factors and carotid intima-media thickness (CIMT).
METHODS: One hundred fifty-nine type 1 diabetic patients and 100 healthy controls were included in the study. We investigated metabolic and anthropometric parameters such as body mass index (BMI), waist circumference, fasting glucose and insulin, serum lipids, 24h ambulatory blood pressure monitoring (ABPM), and CIMT and compared these with those in control subjects (CS).
RESULTS: No difference was found between type 1 diabetic patients and CS in age, weight, waist/hip ratio, triglyceride, HDL-cholesterol level. However in children with type 1 diabetes, total cholesterol (p=0.016),and LDL-cholesterol (p=0.002) levels and CIMT (P<0.001) were greater than those of controls. It was determined that 10% of type 1 diabetic patients had dyslipidemia. In 23.2% of type 1 diabetic patients, ABPM showed arterial hypertension. CIMT was significantly higher in the hypertensive group than in the non-hypertensive group (P=0.003). Twenty-three (14.4%) diabetic patients had nocturnal hypertension. CIMT was significantly greater in the nocturnal hypertensive group (p=0.023). Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) dipping was significantly different in diabetic patients (P<0.001). CIMT was correlated positively with Hba1c (r=0.220, p=0.037), and negatively with SBP dipping (r=-0.362, p=0.020) in the diabetic patients. In stepwise regression analysis, Hba1c and SBP dipping emerged as a significant predictor of CIMT (β=0.300, p=0.044, β=0.398 p=0.009) contributing to 15.58% of its variability.
CONCLUSION: These results provide additional evidence for the presence of subclinical cardiovascular disease (CVD) and its relation to hypertension in type 1 diabetic patients. They also indicate a significant relation between nocturnal hypertension, SBP dipping and increased arterial stiffness. It is also important to note that our findings reveal significant relationships between HBA1c cardiovascular changes and underline the importance of glucose control to predict CVD.
© 2014.

Entities:  

Keywords:  Ambulatory blood pressure; Subclinical cardiovascular disease; Type 1 diabetes

Mesh:

Year:  2013        PMID: 24157221     DOI: 10.1016/j.jdiacomp.2013.09.007

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  15 in total

Review 1.  How should we manage a patient with masked hypertension?

Authors:  Paolo Palatini
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-02-06

Review 2.  Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?

Authors:  Petter Bjornstad; Kim C Donaghue; David M Maahs
Journal:  Lancet Diabetes Endocrinol       Date:  2018-02-20       Impact factor: 32.069

3.  Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.

Authors:  Jeffrey D Lebensburger; Gary R Cutter; Thomas H Howard; Paul Muntner; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2017-04-05       Impact factor: 3.714

Review 4.  Blood pressure (BP) assessment-from BP level to BP variability.

Authors:  Janusz Feber; Mieczyslaw Litwin
Journal:  Pediatr Nephrol       Date:  2015-07-23       Impact factor: 3.714

Review 5.  The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.

Authors:  Jessica Hurtubise; Krystie McLellan; Kevin Durr; Oluwadara Onasanya; Daniel Nwabuko; Joseph Fomusi Ndisang
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

6.  Evidence of Early Diabetic Nephropathy in Pediatric Type 1 Diabetes.

Authors:  Leena Mamilly; Lucy D Mastrandrea; Claudia Mosquera Vasquez; Brett Klamer; Mahmoud Kallash; Ahmad Aldughiem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-28       Impact factor: 5.555

7.  Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies.

Authors:  Mary Katherine Ray; Alana McMichael; Maria Rivera-Santana; Jacob Noel; Tamara Hershey
Journal:  JMIR Diabetes       Date:  2021-06-03

Review 8.  Morinda citrifolia Linn. (Noni) and Its Potential in Obesity-Related Metabolic Dysfunction.

Authors:  Aline Carla Inada; Priscila Silva Figueiredo; Rosângela Aparecida Dos Santos-Eichler; Karine de Cássia Freitas; Priscila Aiko Hiane; Alinne Pereira de Castro; Rita de Cássia Avellaneda Guimarães
Journal:  Nutrients       Date:  2017-05-25       Impact factor: 5.717

Review 9.  Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events?

Authors:  Evgenia Gourgari; Dana Dabelea; Kristina Rother
Journal:  Curr Diab Rep       Date:  2017-11-03       Impact factor: 4.810

10.  Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.

Authors:  Shu-Yang Li; Yoichi Yoshida; Eiichi Kobayashi; Akihiko Adachi; Seiichiro Hirono; Tomoo Matsutani; Seiichiro Mine; Toshio Machida; Mikiko Ohno; Eiichiro Nishi; Yoshiro Maezawa; Minoru Takemoto; Koutaro Yokote; Kenichiro Kitamura; Makoto Sumazaki; Masaaki Ito; Hideaki Shimada; Hirotaka Takizawa; Koichi Kashiwado; Go Tomiyoshi; Natsuko Shinmen; Rika Nakamura; Hideyuki Kuroda; Xiao-Meng Zhang; Hao Wang; Kenichiro Goto; Yasuo Iwadate; Takaki Hiwasa
Journal:  Int J Mol Med       Date:  2020-07-29       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.